Atrial fibrillation: Epidemiology, mechanisms and management

Indian Heart Journal

Volumn 52, Issue 2, 2000, Pages 129-164

  Bhatia, Atul ^a   Sra, Jasbir ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; DIGOXIN; DILTIAZEM; ESMOLOL; METOPROLOL; SOTALOL; VERAPAMIL; WARFARIN;

ANTICOAGULANT THERAPY; CARDIOVERSION; CATHETER ABLATION; CLINICAL FEATURE; DEFIBRILLATION; DYSPNEA; ECONOMIC ASPECT; ELECTROCARDIOGRAM; ELECTROPHYSIOLOGY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART PALPITATION; PROGNOSIS; REVIEW; RISK FACTOR; SINUS RHYTHM; STROKE; THROMBOEMBOLISM; VERTIGO;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS; DEFIBRILLATORS, IMPLANTABLE; HUMANS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SPORTS; TREATMENT OUTCOME;

EID: 0033933410     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (284)

1. Kannel WB, Abbott RD, Savage DD, Mcnamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982; 306: 1018-1022
2. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA 1985; 254: 3449-3453
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly- The Framingham Study. Arch Intern Med 1987; 147: 1561-1564
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988
5. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM, et al. The natural history of lone atrial fibrillation: A population-based study over three decades. N Engl J Med 1987; 317: 669-674
6. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM, et al. For the Collaborative Research Group. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241
7. Manolio TA, Furberg CD, Rautaharju PM, Siscovick D, Newman AB, Borhani NO, et al. Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: The Cardiovascular Health Study. J Am Coll Cardiol 1994; 23: 916-925
8. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AF, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271: 840-844
9. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 1994; 89: 724-730
10. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: Prevalence, incidence and mortality in the Framingham study. Ann Intern Med 1969; 71: 89-105
11. Stanton MS, Miles WM, Zipes DP. Atrial fibrillation and flutter. In: Cardiac electrophysiology from cell to bedside. Zipes DP, Jalife J, ed. Philadelphia: WB Saunders Co.; 1990, pp 735-742
12. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Mortality and hospital costs associated with atrial fibrillation. Circulation 1995; 92: I-40
13. Maglio C, Ayers GM, Tidball EW, Sra J, Dhala A, Blanck Z, et al. Health care utilization and cost of care in patients with symptomatic atrial fibrillation. Circulation 1996; 94: I-169
14. Myerburg RJ, Kessler KM, Castellanos A. Recognition, clinical assessment, and management of arrhythmias and conduction disturbances, In: Hurst's: The heart. Schlant RC, Alexander RW, O'Rourke RA, Roberts R, Sonnenblick EH, ed. 8th ed. New York: McGraw-Hill; 1994, pp 705-758
15. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455-2461
16. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952
17. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, et al. Management of patients with atrial fibrillation: A Statement for Healthcare Professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93: 1262-1277
18. Kerr CR and the Canadian Registry of Atrial Fibrillation (CARAF). Who wants to be treated for atrial fibrillation? Relation of clinical variables to symptoms, In: Nonpharmacologic management of atrial fibrillation. Murgatroyd FD, Camm AJ, ed. Armonk, NY: Futura Pub. Co.; 1997, pp 15-22
19. Takahashi N, Seki A, Imataka K, Fuji J. Clinical features of paroxysmal atrial fibrillation: An observation of 94 patients. Jpn Heart J 1981 22: 143-149
20. Bialy D, Lehmann MH, Schumacher DN, Stienman RT, Meissner MD. Hospitalization for arrhythmias in the United States: Importance of atrial fibrillation. J Am Coll Cardiol 1992; 19: 41A
21. Sopher SM, Camm AJ. Therapy for atrial fibrillaiton: Control of the ventricular response and prevention of recurrence. Coron Artery Dis 1995; 6: 106-114
22. Levy S. Epidemiology and classification of atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: S78-S82
23. Cristal N, Szwarczberg J, Gueron M. Supraventricular arrhythmias in acute myocardial infarction: Prognostic importance of clinical setting; mechanism of production. Ann Intern Med 1975; 82; 35-39
24. Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: A correctable cause of "idiopathic" atrial fibrillation. Am J Cardiol 1979; 44: 9-12
25. Rich EC, Siebold C, Campion B. Alcohol-related acute atrial fibrillation: A case-control study and review of 40 patients. Arch Intern Med 1985; 145: 830-833
26. Szucs MM Jr, Brooks HL, Grossman W, Banas JS Jr, Meister G, Dexter L, et al. Diagnostic sensitivity of laboratory findings in acute pulmonary embolism. Ann Intern Med 1971; 74: 161-166
27. Chagnac Y, Martinovits G, Tadmore R, Goldhammer Y. Paroxysmal atrial fibrillation associated with an attack of multiple sclerosis. Postgrad Med J 1986; 62: 385-387
28. Edwards JD, Wilkins RG. Atrial fibrillation precipitated by acute hypovolaemia. Br Med J 1987; 294: 283-284
29. Cohen L, Larson DW, Strandjord N. Swallowing-induced atrial fibrillation. Circulation 1970; III-145
30. Radford DJ, Izukawa T. Atrial fibrillation in children. Pediatrics 1977; 59: 250-256
31. Belhassen B, Pauzner D, Blieden L, Sherez J, Zinger A, David M, et al. Intrauterine and postnatal atrial fibrillation in the Wolff-Parkinson-White syndrome. Circulation 1982; 66: 1124-1128
32. Till J, Wren C. Atrial flutter in the fetus and young infant: An association with accessory connections. Br Heart J 1992; 67: 80-83
33. Benson DW Jr, Dunnigan A, Benditt DG. Follow-up evaluation of infant paroxysmal atrial tachycardia: Transesophageal study. Circulation 1987; 75: 542-549
34. Roark SF, McCarthy EA, Lee KL, Pritchett EL. Observations on the occurrence of atrial fibrillation in paroxysmal supra ventricular tachycardia. Am J Cardiol 1986; 57: 571-575
35. Johnson WH Jr, Dunnigan A, Fehr P, Benson DW Jr, et al. Association of atrial flutter with orthodromic reciprocating fetal tachycardia. Am J Cardiol 1987; 59: 374-375
36. Garg A, Wadhwa M, Birgersdotter-Green U, Feld G. Electrophysiology study reveals a high incidence of curable supraventricular arrhythmias causing paroxysmal atrial fibrillation in young patients with no structural heart disease. PACE 1999; 22: II-842
37. Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979; 301: 1080-1085
38. Fananapazir L, Packer DL, German LD, Greer GS, Gallagher JJ, Pressley JC, et al. Procainamide infusion test: Inability to identify patients with Wolff-Parkinson-White syndrome who are potentially at risk of sudden death. Circulation 1988; 77: 1291-1296
39. Dreifus LS, Haiat R, Watanabe Y, Arriaga J, Reitman N. Ventricular fibrillation: A possible mechanism of sudden death in patients with Wolff-Parkinson-White syndrome. Circulation 1971; 43: 520-527
40. Furlanello F, Bertoldi A, Dallago M, Glassi A, Fernando F, Biffi A, et al. Atrial fibrillation in elite athletes. J Cardiovasc Electophysiol 1998; 9: S63-S68
41. Coumel P. Neurogenic and humoral influences of the autonomic nervous system in the determination of paroxysmal atrial fibrillation, In: The atrium in health and disease. Atteul P, Coumel P, Janse MJ, ed. Mount Kisco, NY: Futura Publishing Co.; 1989, pp 213-232
42. Catherwood E, Fitzpatrick WD, Greenberg ML, Holzberger PT, Malenka DJ, Gerling BR, et al. Cost effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med 1999; 130: 625-636
43. Stroke risk factors and their impact. National Stroke Association, 1999
44. Pedersen CT. For the DIAMOND Study Group. The effect of atrial fibrillation/flutter on all-cause mortality in patients with heart failure or myocardial infarction with left ventricular dysfunction. PACE 1999; 22: II-719
45. Kieny JR, Sacrez A, Facello A, Arbogast R, Bareiss P, Roul G, et al. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J 1992; 13: 1290-1295
46. Gerstenfeld EP, Mittleman RS. Analysis of symptoms reported by patients with paroxysmal atrial fibrillation undergoing ambulatory Holter monitoring. PACE 1999; 22: II-730
47. Waktare JE, Camm AJ. Acute treatment of atrial fibrillation: Why and when to maintain sinus rhythm. Am J Cardiol 1998; 81: 3C-15C
48. Jenkins LS, Ellenbogan K, Kay N, Giudici M, Jensen N, Martin R, et al. Quality of life in patients with symptomatic atrial fibrillation. Circulation 1995; 92: I-490
49. Paquette M, Roy D, Talajic M, Newman D, Dorian P, et al. For the CTAF Investigators. Women with atrial fibrillation have greater quality of life impairment than men: Results from the Canadian Trial of Atrial Fibrillation. PACE 1999; 22: II-713
50. Rothenberger CJ, Winterberg H. Ueber vorhofflimmern und vorhofflattern. Pflugers Arch 1914; 160: 42-90
51. Engelmann TW. Refraktare phase und kompensatorische ruhe in ihrer bedeutung fuer den herzrhythmus. Pfluegers Arch Ges Physiol 1894-95; 59: 309-349
52. Lewis T. Observations upon flutter and fibrillation: part IV. Impure flutter: Theory of circus movement. Heart 1920; 7: 293-331
53. Garrey WE. Auricular fibrillation. Physiol Rev 1924; 4: 215-250
54. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmias independent of focal discharge. Am Heart J 1959; 58: 59-70
55. Moe GK. A conceptual model of atrial fibrillation. J Electrocardiol 1968; 1: 145-146
56. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Am Heart J 1964; 67: 200-220
57. Allessie MA, Lammers WEJEP, Bonke FIM, et al. Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation, In: Cardiac electrophysiology and arrhythmias. Zipes DP, Jalife J, ed. New York: Grune & Stratton; 1985, pp 265-275
58. Konings KT, Kirchhof CJ, Smeets JR, Wellens HJ, Penn OC, Allessie MA. High-density mapping of electrically induced atrial fibrillation in humans. Circulation 1994; 89: 1665-1680
59. Konings KT, Smeets JL, Penn OC, Wellens HJ, Allessie MA. Configuration of unipolar atrial electrograms during electrically induced atrial fibrillation in humans. Circulation 1997; 95: 1231-1241
60. Cox JL, Canavan TE, Schuessler RB, Cain ME, Lindsay BD, Stone C, et al. The surgical treatment of atrial fibrillation - II: Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991: 101: 406-426
61. Wells JL Jr, Karp RB, Kouchoukos NT, MacLean WA, James TN, Waldo AL. Characterization of atrial fibrillation in man: Studies following open heart surgery. PACE 1978; 1: 426-438
62. Schuessler RB, Grayson TM, Bromberg BI, Cox JL, Boineau JP. Cholinergically mediated tachyarrhythmias induced by a single extrastimulus in the isolated canine right atrium. Circ Res 1992; 71: 1254-1267
63. Botteron GW, Smith JM. Quantitative assessment of the spatial organization of atrial fibrillation in the intact human heart. Circulation 1996; 93: 513-518
64. Gerstenfeld EP, Sahakian AV, Swiryn S. Evidence for transient linking of atrial excitation during atrial fibrillation in humans. Circulation 1992; 86: 375-382
65. Rosenbaum DS, Cohen RJ, Frequency-based measures of atrial fibrillation in man. IEEE-MBS 1990; 12: 582-583
66. Jalife J, Berenfeld O, Skanes A, Mandapati R. Mechanisms of atrial fibrillation: Mother rotors or multiple daughter wavelets, or both? J Cardiovasc Electrophysiol 1998; 9: S2-S12
67. Skanes AC, Mandapati R, Berenfeld O, Davidenko JM, Jalife J. Spatiotemporal periodicity during atrial fibrillation in the isolated sheep heart. Circulation 1998; 98: 1236-1248
68. Jais P, Haissaguerre M, Shah DC, Chouairi S, Gencel L, Hocini M, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997; 95: 572-576
69. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666
70. Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia - III: The "leading circle" concept: Anew model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res 1977; 41: 9-18
71. Smeets JL, Allessie MA, Lammers WJ, Bonke FI, Hollen J. The wavelength of the cardiac impulse and reentrant arrhythmias in isolated rabbit atrium. The role of heart rate, autonomic transmitters, temperature, and potassium. Circ Res 1986; 58: 96-108
72. Cabo C, Pertsov AM, Baxter WT, Davidenko JM, Gray RA, Jalife J, et al. Wave-front curvature as a cause of slow conduction and block in isolated cardiac muscle. Circ Res 1994; 75: 1014-1028
73. Wit AL, Allessie MA. Functional models of reentry: A comparison of anisotropic and leading circle reentry, In: Atrial flutter. Waldo AE, Toubout P, ed. Armonk, NY: Futura Publishing Co; 1996, pp 103-119
74. Allessie MA. Atrial electrophysiologic remodeling: Another vicious circle? J Cardiovasc Electrophysiol 1998; 9: 1378-1393
75. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968
76. Katz AM. T wave "memory": Possible causal relationship to stress-induced changes in cardiac ion channels? J Cardiovasc Electrophysiol 1992; 3: 150-159
77. Lown B, Perlroth MG, Kaidby S, et al. "Cardioversion" of atrial fibrillation: Report on 65 episodes in 50 patients. N Engl J Med 1963; 269: 325-333
78. Crijns HJ, van Wijk LM, van Gilst WH, Kingma JH, van Gelder IC, Lie KI, et al. Acute conversion of atrial fibrillation to sinus rhythm: Clinical efficacy of flecainide acetate - Comparison of two regimes. Eur Heart J 1988; 9: 634-638
79. Attuel P, Childers RW, Haissaguerre M, et al. Failure in the rate adaptation of the atrial refractory periods: New parameter to assess atrial vulnerability. PACE 1984; 7: 1382
80. Attuel P, Childers RW, Cauchemez B, Poveda J, Mugica J, Coumel P. Failure in the rate adaptation of the atrial refractory period: Its relationship to vulnerability. Intern J Cardiol 1982; 2: 179-197
81. Attuel P, Leclercq JF, Coumel P. Atrial electrophysiological substrate remodeling after tachycardia in patients with and without atrial fibrillation. PACE 1995; 18: II-804
82. Boutjdir M, Le Heuzey JY, Lavergne T, Chauvaud S, Guize L, Carpentier A, et al. Inhomogeneity of cellular refractoriness in human atrium: Factor of arrhythmia? PACE 1986; 9: 1095-1100
83. Capucci A, Biffi M, Boriani G, Ravelli F, Nollo G, Sabbatini P, et al. Dynamic electrophysiological behavior of human atria during paroxysmal atrial fibrillation. Circulation 1995; 92: 1193-1202
84. White CW, Kerber RF, Weiss HR, Marcus HL. The effects of atrial fibrillation on atrial pressure-volume and flow relationships. Circ Res 1982; 51: 205-215
85. White C, Holida M, Marcus M. Effects of acute atrial fibrillation on the vasodilator reserve of the canine atrium. Cardiovasc Res 1986; 20: 683-689
86. Leistad E, Christensen G, Ilebekk A. Right and left atrial diameters during incremental pacing in pigs. Am J Physiol 1991; 260: H973-H978
87. Kaseda S, Zipes DP. Contraction-excitation feedback in the atria: A cause of changes in refractoriness. J Am Coll Cardiol 1988; 11: 1327-1336
88. Klein LS, Miles WM, Zipes DP. Effect of atrioventricular interval during pacing or reciprocating tachycardia on atrial size, pressure, and refractory period: Contraction-excitation feedback in human atrium. Circulation 1990; 82: 60-68
89. Boyden PA, Hoffman BF. The effects on atrial electrophysiology and structure of surgically induced right atrial enlargement in dogs. Circ Res 1981; 49: 1319-1331
90. Manning WJ, Leeman DE, Gotch PJ, Come PC. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol 1989; 13: 617-623
91. Manning WJ, Silverman DI, Katz SE, Riley MF, Come PC, Doherty RM, et al. Impaired left atrial mechanical function after cardioversion: Relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23: 1535-1540
92. Kottkamp H, Hindricks G, Breithardt G. Role of anticoagulant therapy in atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: S86-S96
93. Petersen P, Boysen G, Godtfredsen J, Anderson ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation- The Copenhagen AFASAK study. Lancet 1989; 1: 175-179
94. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511
95. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: Final results. Circulation 1991; 84: 527-539
96. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. For the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-1412
97. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-355
98. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691
99. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262
100. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457
101. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5
102. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992; 116: 6-12
103. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-546
104. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin plus versus low-intensity aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996; 348: 633-638
105. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5-10
106. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest 1992; 102: 426S-433S
107. Knight BP, Morady F. Optimal management of the patient with an episode of atrial fibrillation in and out of the hospital: Acute cardioversion or not? J Cardiovasc Electrophysiol 1999; 10: 425-432
108. Weigner MJ, Caulfield TA, Danias PG, Silverman DI, Manning WJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126: 615-620
109. Danias PG, Caulfield TA, Weigner MJ, Silverman DJ, Manning WJ. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998; 31: 588-592
110. Bjerkelund CJ, Orning OM. The efficacy of anticoagulation therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol 1969; 23: 208-216
111. Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 1989; 63: 745-746
112. Arnold AZ, Mick MJ, Mazurek, RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992; 19: 851-855
113. Roy D, Marchand E, Gagne P, Chabot M, Cartier R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J 1986; 112: 1039-1043
114. Manning WJ, Silverman DI, Katz SE, Riley MF, Doherty RM, Munson JT, et al. Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1995; 75: 624-626
115. Levine HJ, Pauker SA, Eckman MH. Antithrombotic therapy in valvular heart disease. Chest 1995; 108: 360S-370S
116. Zoll PM, Linenthal AJ, Gibson W, et al. Termination of ventricular fibrillation in man by externally applied electric countershock. N Engl J Med 1956; 254: 727-732
117. Lown BR, Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias: Use of synchronized capacitor discharge. JAMA 1962; 182: 548-555
118. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967; 29: 469-489
119. Ferris LP, King BG, Spence PW, et al. Effect of electric shock on the heart. Elec Engg 1936; 55: 498-515
120. Wiggers CJ, Wegria R. Ventricular fibrillation due to single localized induction and condenser shocks applied during the vulnerable phase of ventricular systole. Am J Physiol 1940; 128: 500-505
121. Kerber RE, Grayzel J, Hoyt R, et al. Transthoracic resistance in human defibrillation: Influence of body weight, chest size, serial shocks, paddle size, and paddle contact pressure. Circulation 1981; 63: 676-682
122. Weaver WD, Cobb LA, Copass MK, et al. Ventricular defibrillation: A comparative trial using 175-J and 320-J shocks. N Engl J Med 1982; 307: 1101-1106
123. Ricard P, Levy S, Trigano J, et al. Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation. Am J Cardiol 1997; 79: 815-816
124. Lerman BB, Deale OC. Relation between transcardiac and transthoracic current during defibrillation in humans. Circ Res 1990; 67: 1420-1426
125. Kerber RE, Martins JB, Kelly KJ, et al. Self-adhesive, pre-applied electrode pads for defibrillation and cardioversion. J Am Coll Cardiol 1984; 3: 815-820
126. Kerber RE, Jensen SR, Grayzel J, et al. Elective cardioversion: Influence of paddle-electrode location and size on success rates and energy requirements. N Engl J Med 1981; 305: 658-662
127. Saliba W, Juratli N, Chung MK, et al. Higher energy synchronized external direct current cardioversion for refractory atrial fibrillation. J Am Coll Cardiol 1999; 34: 2031-2034
128. Tebbe U, Carlsson J, Seidl K, et al. Cardioversion in atrial fibrillation: Results and complications in 1,152 prospective patients. Study Group of the Working Society of Leading Cardiologic Hospital Physicians. Med Klin 1995; 90: 681-687
129. Falcone RA, Morady F, Armstrong WF. Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Am J Cardiol 1996; 78: 435-439
130. Kouwenhoven WB, Milnor WR, Knickerbocker GG, et al. Closed-chest defibrillation of the heart. Surgery 1957; 42: 550-561
131. Jones JL. Waveforms for implantable cardioverter defibrillators and transchest defibrillation, In: Defibrillation of the heart. Tacker WA, ed. St. Louis: Mosby-Year Book; 1994, pp 46-81
132. Kumagai K, Yamanouchi Y, Hiroki T, et al. Effects of transcatheter cardioversion on chronic lone atrial fibrillation. PACE 1991; 14: 1571-1575
133. Levy S, Lauribe P, Dolla E, et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation. 1992; 86: 1415-1420
134. Levy S, Ricard P, Lau C, et al. Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. J Am Coll Cardiol 1997; 29: 750-755
135. Alt E, Schmitt C, Ammer R, et al. Effect of electrode position on outcome of low-energy intracardiac cardioversion of atrial fibrillation. Am J Cardiol 1997; 79: 621-625
136. Dixon EG, Tang AS, Wolf PD, et al. Improved defibrillation thresholds with large contoured epicardial electrodes and biphasic waveforms. Circulation 1987; 76: 1176-1184
137. Cooper RA, Alferness CA, Smith WM, et al. Internal cardioversion of atrial fibrillation in sheep. Circulation 1993; 87: 1673-1686
138. Ortiz J, Niwano S, Abe H, et al. Transvenous atrial defibrillation in two canine models of atrial fibrillation. J Am Coll Cardiol 1994; 23: 125A
139. Powell AC, Garan H, McGovern BA, et al. Low energy conversion of atrial fibrillation in the sheep. J Am Coll Cardiol 1992; 20: 707-711
140. Wharton JM, Johnson EE. Catheter based atrial defibrillation. PACE 1994; 17: 1058-1066
141. Chen PS, Wolf PD, Claydon FJ, et al. The potential gradient field created by epicardial defibrillation electrodes in dogs. Circulation 1986; 74: 626-636
142. Wharton JM, Wolf PD, Smith WM, et al. Cardiac potential and potential gradient fields generated by single, combined, and sequential shocks during ventricular defibrillation. Circulation 1992; 85: 1510-1523
143. Krum D, Hare J, Mughal K, et al. Optimization of shocking lead configuration for transvenous atrial defibrillation. J Cardiovasc Electrophysiol 1998; 9: 998-1003
144. Tacker WA, Schoenlein WE, Janas W, et al. Catheter electrode evaluation for transvenous atrial defibrillation. PACE 1993; 16: II-853
145. Keelan ET, Krum D, Hare J, et al. Safety of atrial narrow and wide QRS complexes during atrial pacing protocols simulating atrial fibrillation in dogs. Circulation 1997; 96: 2022-2030
146. Barold HS, Wharton JM. Ventricular fibrillation resulting from synchronized internal atrial defibrillation in a patient with ventricular preexcitation. J Cardiovasc Electrophysiol 1997; 8: 436-440
147. Ayers GM, Alferness CA, Ilina M, et al. Ventricular proarrhythmic effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation. Circulation 1994; 89: 413-422
148. Kumagai K, Yamanouchi Y, Tashiro N, et al. Low energy synchronous transcatheter cardioverson of atrial flutter/fibrillation in the dog. J Am Coll Cardiol 1990; 16: 497-501
149. Sra J, Biehl M, Blanck Z, et al. Spontaneous reinitiation of atrial fibrillation following transvenous atrial defibrillation. PACE 1998; 21: 1105-1110
150. Goodman DJ, Rossen RM, Cannom DS, Rider AK, Harrison DC. Effect of digoxin on atrioventricular conduction: Studies in patients with and without cardiac autonomic innervation. Circulation 1975; 51: 251-256
151. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: The effect of digoxin. Br Heart J 1990; 63: 225-227
152. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: A multicenter study. J Am Coll Cardiol 1991; 18: 891-897
153. Waxman HL, Myerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: A double-blind randomized cross-over study. Ann Intern Med 1981; 94: 1-6
154. Reiter MJ, Shand DG, Aanonsen LM, Wagoner, McCarthy E, Pritschett EL. Pharmacokinetics of verapamil: Experience with a sustained intravenous infusion regimen. Am J Cardiol 1982; 50: 716-721
155. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: A randomized, double-blinded trial. Ann Intern Med 1987; 106: 503-506
156. Anderson S, Blanski L, Byrd RC, Das G, Engler R, Laddu A, et al. Comparison of the efficacy and safety of esmolol, a short-acting beta-blocker, with placebo in the treatment of supraventricular tachyarrhythmias: The Esmolol vs Placebo Multicenter Study Group. Am Heart J 1986; 111: 42-48
157. David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 1979; 44: 1378-1382
158. Salerno DM, Dias VC, Kleiger RE, Tschita VH, Sung RJ, Sami M, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter: The Diltiazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1989; 63: 1046-1051
159. Rinkenberger RL, Prystowsky EN, Heger JJ, Troup PJ, Jackman WM, Zipes DP. Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation 1980; 62: 996-1010
160. Fenster PE, Comess KA, Marsh R, Katzenberg C, Hager WD. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 1983; 106: 501-504
161. Madrid AH, Moro C, Marin-Huerta E, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J 1993; 14: 1127-1131
162. Stambler BS, Wood MA, Belz MK, et al. Electrophysiologic determinants of pharmacologic conversion of human atrial fibrillation and flutter: Enhanced efficay of ibutilide, a new class III antiarrhythmic drug. Circulation 1993; 10: I-445
163. Ellenbogen KA, Stambler BS, Wood MA, Perry KT, Wakefield LK, VanderLught JT. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study. J Am Coll Cardiol 1996; 28: 130-136
164. Goy JJ, Kaufmann U, Kappenberger L, Sigwart U. Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. Am J Cardiol 1988; 62: 38D-40D
165. Bianconi L, Dinelli M, Pappalardo A, et al. Comparison of intravenously-administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study. Circulation 1995; 92: I-774
166. Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, Garcia-Dorado D, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 1996; 27: 1079-1082
167. Fujiki A, Yoshida S, Tani M, Inoue H. Efficacy of class Ia anti-arrhythmic drugs in converting atrial fibrillation unassociated with organic heart disease and their relation to atrial electrophysiologic characteristics. Am J Cardiol 1994; 74: 282-283
168. Borgeat A, Goy J, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986; 58: 496-498
169. Lewis T. The value of quinidine in cases of auricular fibrillation and methods of studying the clinical reaction Am J Med Sci 1922; 163: 781-794
170. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990; 82; 1106-1116
171. Natale A, Blanck Z, Deshpande S, et al. Current concerns and future directions in the pharmacological treatment of atrial fibrillation, In: Atrial arrhythmias: state of the art. DiMarco JP, Prystowsky EN, ed. Armonk, NY: Futura Publishing Co.; 1995, pp 387-401
172. Kowey PR. Pharmacological effects of antiarrhythmic drugs. Review and update. Arch Intern Med 1998; 158; 325-332
173. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandarai AK, et al and the Flecainide Supraventricular Tachycardia Study Group. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989; 80: 1557-1570
174. Kerr CR, Klein GJ, Axelson JE, Cooper JC. Propafenone for prevention of recurrent atrial fibrillation. Am J Cardiol 1988; 61: 914-916
175. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990; 82: 1932-1939
176. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71: 558-563
177. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57: 124-127
178. Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, et al. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985; 6: 1402-1407
179. Brodsky MA, Allen BJ, Walker CJ III, Casey TP, Luckett CR, Henry WL.
180. Blevins RD, Kerin NZ, Benaderet D, Frumin H, Faitel K, Jarandilla R, et al. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 1987; 147: 1401-1404
181. Stevenson WG, Rieders D, Nademanee K, et al. In: Control of cardiac arrhythmias by lengthening repolarization. Singh BN, ed. New York: Futura Publishing Co.; 1988, pp 419-433
182. Gosselink AT, Crijns HJ, Van Gelder IC, Hillege H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267: 3289-3293
183. Dusman RE, Stanton MS, Miles WM, Klein LS, Zipes DP, Fineberg NS, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82: 51-59
184. Middlekauff HR, Stevenson WG, Saxon LA, Stevenson LW. Amiodarone and torsades de pointes in patients with advanced heart failure. Am J Cardiol 1995; 76: 499-502
185. Gwilt M, Arrowsmith JE, Blackburn KJ, Burgess RA, Cross PE, Dalyrymple HW, et al. UK-68, 798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 1991; 256: 318-324
186. Singh SN, Berk MR, Yellen LG, et al. Efficacy and safety of oral dofetilide in maintaining normal sinus rhythm in patients with atrial fibrillation/flutter: A multi-center study. Circulation 1997; 96: 1-383
187. Greenbaum R, Campbell TJ, Channer KS, et al. Conversion of AF and maintenance of sinus rhythm by dofetilide. Eur Heart J 1998; 19: 661
188. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999; 341: 857-865
189. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68: 335-341
190. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990; 15: 698-707
191. Haverkamp W, Shenasa M, Borggrefe M, et al. Torsades de pointes, In: Cardiac electrophysiology: From cell to bedside. Zipes DP, Jalife J, ed. 2nd edn. Philadelphia: WB Saunders Publishing Co.; 1994
192. Hohnloser S, Arendts W, Quart B. Incidence, type, and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF. PACE 1992; 15: II-551
193. Nguyen PT, Scheinman MM, Seger J. Polymorphous ventricular tachycardia: Clinical characterization, therapy, and the QT interval. Circulation 1986; 74: 340-349
194. Minardo JD, Heger JJ, Miles WM, Zipes DP, Prystowsky EN. Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med 1988; 319: 257-262
195. Roden DM, Thompson KA, Hoffman BF, Woosley RL. Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol 1986; 8: 73A-78A
196. Leitch J, Klein G, Yee R, Guiraudon G. Sinus node-atrioventricular node isolation: Long-term results with the "corridor" operation for atrial fibrillation. J Am Coll Cardiol 1991; 17: 970-975
197. Cox JL, Schuessler RB, D'Agostino HJ Jr., Stone CM, Chang BC, Cain ME, et al. The surgical treatment of atrial fibrillation: III. development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991; 101: 569-583
198. Cox JL, Schuessler RB, Lappas DG, Boineau JP. An 8 1/2-year clinical experience with surgery for atrial fibrillation. Ann Surg 1996; 224: 267-275
199. Kawaguchi AT, Kosakai Y, Sasako Y, Eishi K, Nakano K, Kawashima Y. Risks and benefits of combined maze procedure for atrial fibrillation associated with organic heart disease. J Am Coll Cardiol 1996; 28: 985-990
200. Melo J, Adragao P, Neves J, Parreira L, Morgado F, Bonhorst D, et al. Radiofrequency pulmonary veins isolation during mitral valve surgery to prevent atrial fibrillation: Assessment of one-year results. PACE 1998; 21: II-881
201. Krum D, Kress D, Chekanov V, Hare J, Mughal K, Mousavi-Javardi R, et al. Radiofrequency ablation of chronic atrial fibrillation using endocardial, left atrial appendage and pulmonary vein lesions. PACE 1999; 22: II-905
202. Kress D, Krum D, Hare J, et al. Experience with an epicardial approach to ablation of a persistent atrial fibrillation model: Comparison to endocardial ablation. Circulation 1999; 100: I-433
203. Tanigawa M, Fukatani M, Konoe A, Isomoto S, Kadena M, Hashiba K. Prolonged and fractionated right atrial electrograms during sinus rhythm in patients with paroxysmal atrial fibrillation and sick sinus node syndrome. J Am Coll Cardiol 1991; 17: 403-108
204. Keane D, Stafford P, Baker S, Lewis S, Jackson G, Vincent R. Signal-averaged electrocardiography of the sinus and paced P wave in sinus node disease. PACE 1995; 18: 1346-1353
205. Attuel P, Pellerin D, Mugica J, Coumel P. DDD pacing: An effective treatment modality for recurrent atrial arrhythmias. PACE 1988; 11: 1647-1654
206. Andersen HR, Thuesen L, Bagger JP, Vesterlund P, Thomsen PE. Prospective randomized trial of atrial versus ventricular pacing in sick sinus syndrome. Lancet 1994; 344: 1523-1528
207. Delfaut P, Saksena S, Prakash A, Krol RB. Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention. J Am Coll Cardiol 1998; 32: 1900-1908
208. Saksena S, Prakash A, Hill M, Krol RB, Munsif AN, Matthew PP, et al. Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing. J Am Coll Cardiol 1996; 28: 687-694
209. Saksena S, Delfaut P, Prakash A, Kaushik RR, Krol RB. Multisite electrode pacing for prevention of atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: S155-S162
210. Mehra R. How might pacing prevent atrial fibrillation? In: Nonpharmacological management of atrial fibrillation. Murgatroyd FD, Camm AJ, ed. Armonk, New York: Futura Publishing Co.; 1997, pp 283-307
211. Sra JS, Maglio C, Dhala A, Blanck Z, Biehl M, Deshpande S, Keelan ET, Jazareri MR, Akhtar M. Feasibility of atrial fibrillation detection and use of a preceding synchronization interval as a criterion for shock delivery in humans with atrial fibrillation. J Am Coll Cardiol 1996; 28: 1532-1538
212. Wellens HJ, Lau CP, Luderitz B, et al. Atrioverter: An implantable device for the treatment of atrial fibrillation. Circulation 1998; 98: 1651-1656
213. Sra J, Jazayeri MR, Dhala A, et al. Implantable atrial defibrillator for atrial fibrillation. Wis Med J 1998; 11: 37-39
214. Fellows CL, Hoyt RH, Sra JS, et al. and the Metrix™ Investigators. Clinical use of the Metrix implantable atrial defibrillator. PACE 1998; 21: II-986
215. Wharton M, Santini M. Treatment of spontaneous atrial tachyarrhythmias with the Medtronic 7250 Jewel AF: Worldwide clinical experience. PACE 1998; 21: II-986
216. Scheinman MM, Morady F, Hess DS, Gonzalez R. Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias. JAMA 1982; 248: 851-855
217. Jackman WM, Wang XZ, Friday KJ, Roman CA, Moulton KP, Beckman KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 1991; 324: 1605-1611
218. Walsh EP, Saul JP, Hulse JE, Rhodes LA, Hordof AJ, Meger JE, et al. Transcatheter ablation of ectopic atrial tachycardia in young patients using radiofrequency current. Circulation 1992; 86: 1138-1146
219. Jazayeri MR, Hempe SL, Sra JS, Dhala A, Blanck Z, Deshpande S, et al. Selective transcatheter ablation of the fast and slow pathways using radiofrequency energy in patients with atrioventricular nodal reentrant tachycardia. Circulation 1992; 85: 1318-1328
220. Kay GN, Plum VJ. The present role of radiofrequency catheter ablation in the management of cardiac arrhythmias. Am J Med 1996; 100: 344-356
221. Feld GK, Fleck RP, Chen PS, Boyce LA, Bahnson TD, Stein JB, et al. Radiofrequency catheter ablation for the treatment of human type 1 atrial flutter: Identification of a critical zone in the reentrant circuit by endocardial mapping techniques. Circulation 1992; 86: 1233-1240
222. Swartz JF, Pellersels G, Silvers J, Patton L, Cervantez D. A catheter-based curative approach to atrial fibrillation in humans. Circulation 1994; 90: I-335
223. Haissaguerre M, Jais P, Shah D, Gencel L, Pradeau V, Garrigues S. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7: 1132-1144
224. Gaita F, Riccardi R, Calo L, Scaglione M, Garberoglio L, Antolini R, et al. Atrial mapping and radiofrequency catheter ablation in patients with idiopathic atrial fibrillation: Electrophysiological findings and ablation results. Circulation 1998; 97: 2136-2145
225. Man KC, Daoud E, Knight B, Weiss R, Bahu M, Harvey M, et al. Right atrial radiofrequency catheter ablation of paroxysmal atrial fibrillation. J Am Coll Cardiol 1996; 27: 188A
226. Maloney JD, Milner L, Barold S, Czerska B, Markel M. Two-sided biatrial linear and focal ablation to restore sinus rhythm in patients with refractory chronic atrial fibrillation: Procedure, experience and follow-up beyond one year. PACE 1998; 21: 2527-2532
227. Haines DE, Langberg JJ, Lesh, MD, Leon AR, Mitchell MM, deLurgio DB, et al. Catheter ablation of atrial fibrillation using the multiple electrode catheter ablation (MECA) system: Preliminary clinical trial results. PACE 1998; 21: II-832
228. Kuck KH, Ernst S, Khanedani A, Braun E, Ouyang F, Volkmer M, et al. Clinical follow-up after primary catheter-based ablation of atrial fibrillation using the CARTO system. PACE 1998; 21: II-868
229. Sherman M, Simpson J, Bowe W, Castellano T, Desai JM, Hall JA, et al. A system for the creation of long linear lesions utilizing duty cycle controlled phased radiofrequency energy. PACE 1998; 21: II-883
230. Garg A, Finneran W, Mollerus M, Birgerdotten-Green U, Fujimura O, Tone L. Right atrial compartmentalization using radiofrequency catheter ablation for management of patients with refractory atrial fibrillation. J Cardiovasc Electrophysiol 1999; 10: 763-771
231. Epstein MR, Kapp LD, Martindill M, Lulu JA, Triedman JK, Calkins H, et al. Embolic complications associated with radiofrequency catheter ablation. Atakr Investigators Group. Am J Cardiol 1996; 77: 655-658.
232. Hindricks G. The Multicenter European Radiofrequency Survey (MERFS): Complications of radiofrequency catheter ablation of arrhythmias. Eur Heart J 1993; 14: 1644-1653
233. Feld GK, Fleck RP, Fujimura O, Prothro DL, Bahnson TD, Ibarra M. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation 1994; 90: 2299-2307
234. Narasimhan C, Blanck Z, Akhtar M. Atrioventricular nodal modification and atrioventricular junctional ablation for control of ventricular rate in atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: S146-S150
235. Chen SA, Lee SH, Chiang CE, Tai CT, Wu TJ, Cheng CC, et al. Electrophysiological mechanisms in successful radiofrequency catheter modification of atrioventricular junction for patients with medically refractory paroxysmal atrial fibrillation. Circulation 1996; 93: 1690-1701
236. Williamson BD, Man KC, Daoud E, Niebauer M, Strickberger SA, Morady F. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994; 331: 910-917
237. Morady F, Hasse C, Strickberger A, Man KC, Daoud E, Bogun F, et al. Long-term follow-up after radiofrequency modification of the atrioventricular node in patient with atrial fibrillation. J Am Coll Cardiol 1997; 29: 113-121
238. Scheinman MM, Evans-Bell T. Catheter ablation of the atrioventricular junction: A report of the Percutaneous Mapping and Ablation Registry. Circulation 1984; 70: 1024-1029
239. Langberg JJ, Chin MC, Rosenqvist M, Cockrell J, Dullet N, Van Hare G, et al. Catheter ablation of the atrioventricular junction with radiofrequency energy. Circulation 1989; 80: 1527-1535
240. Yeung-Lai-Wah JA, Alison JF, Lonergan L, Mohama R, Leather R, Kerr CR. High success rate of atrioventricular node ablation with radiofrequency energy. J Am Coll Cardiol 1991; 18: 1753-1758
241. Sousa J, El-Atassi R, Rosenheck S, Calkins H, Langberg J, Morady F. Radiofrequency catheter ablation of the atrioventricular junction from the left ventricle. Circulation 1991; 84: 567-571
242. Feld GK. Radiofrequency catheter ablation versus modification of the AV node for control of rapid ventricular response in atrial fibrillation. J Cardiovasc Electrophysiol 1995; 6: 217-228
243. Fitzpatrick AP, Kourouyan HD, Siu A, Lee RJ, Lesh MD, Epstein LM, et al. Quality of life and outcomes after radiofrequency Hisbundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996; 131: 499-507
244. Twidale N, Sutton K, Bartlett L, Dooley A, Winstanley S, Heddle W, et al. Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias. PACE 1993; 16: 1275-1284
245. Jensen SM, Bergfeldt L, Rosenqvist M. Long-term follow-up of patients treated by radiofrequency ablation of the atrioventricular junction. PACE 1995; 18: 1609-1614
246. Geelan P, Brugada J, Andries E, Brugada P. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. PACE 1997; 20: 343-348
247. Benditt DG, Mianulli M, Fetter J, Benson DW Jr, Dunnigan A, Molina A, et al. Single-chamber cardiac pacing with activity-initiated chronotropicresponse: Evaluation by cardiopulmonary exercise testing. Circulation 1987; 75: 184-191
248. Fananapazir L, Bennett DH, Monks P. Atrial synchronized ventricular pacing: Contribution of the chronotropic response to improved exercise performance. PACE 1983; 6: 601-608
249. Mond HG, Barold SS. Dual chamber, rate adaptive pacing in patients with paroxysmal supraventricular tachyarrhythmias: Protective measures for rate control. PACE 1993; 16; 2168-2185
250. Gianfranchi L, Brignole M, Menozzi C, Lolli G, Bottoni N. Progression of permanent atrial fibrillation after atrioventricular junction ablation and dual-chamber pacemaker implantation in patients with paroxysmal atrial tachyarrhythmias. Am J Cardiol 1998; 81: 351-354
251. The Planning and Steering Committees of the AFFIRM Study for the NHLBI AFFIRM Investigators: Atrial fibrillation follow-up investigation of rhythm management-the AFFIRM study design. Am J Cardiol 1997; 79: 1198-1202
252. Hohnloser SH, Kuck KH. Atrial fibrillation: Maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: The PIAF trial. PACE 1997; 20: 1989-1992
253. Sopher SM, Camm AJ. New trials in atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: S211-S215
254. Leitch JW, Thomson D, Baird DK, Jarris PJ. The importance of age as a predictor of atrial fibrillation and flutter after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1990; 100: 338-342
255. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of post-operative atrial arrhythmias. Ann Thorac Surg 1993; 56: 539-549
256. Hashimoto K, Ilstrup DM, Schaff HV. Influence of clinical and hemodynamic variables on risk of supraventricular tachycardia after coronary artery bypass. J Thorac Cardiovasc Surg 1991; 101: 56-65
257. Cox JL. A perspective of post-operative atrial fibrillation in cardiac operations. Ann Thorac Surg 1993; 56: 405-409
258. Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med 1997; 336: 1429-1434
259. Waldo AL, Henthorn RW, Epstein AE, Plumb VJ. Diagnosis and treatment of arrhythmias during and following open heart surgery. Med Clin North Am 1984; 68: 1153-1169
260. Fuller JA, Adams GG, Buxton B. Atrial fibrillation after coronary artery bypass grafting: Is it a disorder of the elderly? J Thorac Cardiovasc Surg 1989; 97: 821-825
261. Crosby LH, Pifalo WB, Woll KR, Burkholder JA. Risk factors for atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 1990; 66: 1520-1522
262. Pavri BB, O'Nunain SS, Newell JB, Ruskin JN, William G. Prevalence and prognostic significance of atrial arrhythmias after orthotopic cardiac transplantation. J Am Coll Cardiol 1995; 25: 1673-1680
263. Michelucci A, Padeletti L, Porciani MD, et al. Dispersion of refractoriness and atrial fibrillation, In: Atrial fibrillation mechanisms and therapeutic strategies. Olsson SB, Allessie MA, Campbell RWF, ed. Armonk, New York: Futura Publishing Co.; 1994, pp 81-107
264. Steinberg JS, Zelenkofske S, Wong SC, Gelernt M, Sciacca R, Menchavez E. Value of the P-wave signal-averaged ECG for predicting atrial fibrillation after cardiac surgery. Circulation 1993; 88: 2618-2622.
265. Klein M, Evans SJ, Blumberg S, Cataldo L, Bodenheimer MM. Use of P-wave-triggered, P-wave signal-averaged electrocardiogram to predict atrial fibrillation after coronary artery bypass surgery. Am Heart J 1995; 129: 895-901
266. Smith PK, Buhrman WC, Levett JM, Ferguson TB Jr, Holman WC, Cox JL. Supraventricular conduction abnormalities following cardiac operations: A complication of inadequate atrial preservation. J Thorac Cardiovasc Surg 1983; 85; 105-115
267. Mullen JC, Khan N, Weisel RD, Christakis CT, Teoh KH, Madonik M, et al. Atrial activity during cardioplegia and postoperative arrhythmias. J Thorac Cardiovasc Surg 1987; 94: 558-565
268. The Warm Heart Investigators. Randomized trial of normothermic versus hypothermic coronary bypass surgery. Lancet 1994; 343; 559-563
269. Fontan F, Madonna F, Naftel DC, Kirkland JW, Blackstone EH, Digerness S. Modifying myocardial management in cardiac surgery: A randomized trial. Eur J Cardiothorac Surg 1992; 6: 127-136
270. Butler J, Chong JL, Rocker GM, Pillai R, Westaby S. Atrial fibrillation after coronary artery bypass grafting: A comparison of cardioplegia versus intermittent aortic cross-clamping. Eur J Cardiothorac Surg 1993; 7: 23-25
271. Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, et al. Predictors of atrial fibrillation after coronary artery surgery: Current trends and impact on hospital resources. Circulation 1996; 94: 390-397
272. Reed GL III, Singer DE, Picard EH, DeSanctis RW. Stroke following coronary-artery bypass surgery: A case-control estimate of the risk from carotid bruits. N Engl J Med 1988; 319: 1246-1250
273. Frost L, Molgaard H, Christiansen EH, Hjortholm K, Paulsen PK, Thomsen PE. Atrial fibrillation and flutter after coronary artery bypass surgery: Epidemiology, risk factors, and preventive trials. Intern J Cardiol 1992; 36: 253-261
274. Kowey PR, Taylor JE, Rials SJ, Marinchak RA. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol 1992; 69: 963-965
275. Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery: A meta-analysis of randomized control trials. Circulation 1991; 84: III236-III244
276. Abel RM, van Gelder HM, Pores IH, Liguori J, Gielchinsky I, Parsonnet V. Continued propranolol administration following coronary bypass surgery: Antiarrhythmic effects. Arch Surg 1983; 118: 727-31
277. Silverman NA, Wright R, Levitsky S. Efficacy of low-dose propranolol in preventing post-operative supraventricular tachyarrhythmias: A prospective, randomized study. Ann Surg 1982; 196: 194-197
278. Laub GW, Janeira L, Muralidharan S, Riebman JB, Chen C, Neery M, et al. Prophylactic procainamide for prevention of atrial fibrillation after coronary artery bypass grafting: A prospective, double-blind, randomized, placebo-controlled pilot study. Crit Care Med 1993; 21: 1474-1478
279. Gold MR, O'Gara PT, Buckley MJ, DeSanctis RW. Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol 1996; 78: 975-979
280. Daoud EG, Strickberger SA, Man KC, Goyal R, Deeb GM, Bolling SF, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997; 337: 1785-1791
281. Redle JD, Khurana S, Marzan R, McCullough PA, Stewart JR, Westveer DC. Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery. Am Heart J 1999; 138: 144-150
282. Gerstenfeld EP, Hill MR, French SN, Mehra R, Rofino K, VanderSalm TJ, et al. Evaluation of right atrial and biatrial temporary pacing for the prevention of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 1999; 33: 1981-1988
283. Foster RH, Wilde MI, Markham A. Ibutilide: A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs 1997; 54: 312-330
284. Liebold A, Wahba A, Birnbaum DE. Low-energy cardioversion with epicardial wire electrodes: New treatment of atrial fibrillation after open heart surgery. Circulation 1998; 98: 883-886